PURPOSEThe clinical course of pulmonary carcinoids ranges from indolent to fatal disease, suggesting that specific molecular alterations drive progression toward the fully malignant state. A similar spectrum of clinical phenotypes occurs in pediatric …Activation of telomerase defines poor clinical outcome in patients with pulmonary carcinoids.
PDAC is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens
Some scientists believe that microbes might play a part in Alzheimer’s disease development. There are several theories about how and why this occurs. Microbes that…
Antibody-drug conjugates (ADCs) are a rapidly evolving class of anti-cancer drugs with a significant impact on management of hematological malignancies including diffuse large B-cell lymphoma…
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment…
Don’t forget the power of a strong doctor-patient relationship
Canada Healthwatch | The most important health news, in one place. 🍁
Nature Medicine – This analysis of the registry database DESCAR-T of more than 3,000 pediatric and adult patients with hematological malignancies who received CAR T cell…
Vinay Prasad, MD, leads the roundtable discussion with Aaron Goodman, MD, and Al-Ola Abdallah, MD
Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?
After brain injury, some patients are no longer able to respond to the world around them. Is this really the case?
